MCM
VKTX icon

Monimus Capital Management’s Viking Therapeutics VKTX Stock Holding History

Monimus Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.59M Sell
66,502
-1,339
-2% -$43.3K 0.6% 48
2026
Q1 		$2.21M Buy
67,841
+56,399
+493% +$1.81M 0.61% 45
2025
Q4 		$403K Sell
11,442
-18,535
-62% -$657K 0.27% 57
2025
Q3 		$788K Buy
29,977
+6,445
+27% +$192K 0.49% 47
2025
Q2 		$624K Buy
23,532
+889
+4% +$23.4K 0.45% 47
2025
Q1 		$547K Buy
22,643
+1,637
+8% +$51.7K 0.46% 41
2024
Q4 		$845K Buy
+21,006
New +$1.2M 0.8% 38

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Monimus Capital Management's VKTX Position: Q2 2026 in Review

Monimus Capital Management reduced its Viking Therapeutics (VKTX) stake by 2% in Q2 2026, selling an estimated $43.3K and leaving 66,502 shares worth $2.59M. The position accounts for 0.6% of the portfolio, ranked #48.

Monimus Capital Management first reported a position in VKTX in Q4 2024 and has held it in 7 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Monimus Capital Management held 66,502 shares of Viking Therapeutics worth $2.59M as of Q2 2026.
  • Monimus Capital Management sold 1,339 Viking Therapeutics shares in Q2 2026, an estimated $43.3K.
  • Viking Therapeutics made up 0.6% of Monimus Capital Management's portfolio in Q2 2026, its #48 holding.
  • Monimus Capital Management first reported a position in Viking Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Monimus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.